Notable Wednesday Option Activity: ASTS, WVE, BEAM

Wave Life Sciences (WVE) and Beam Therapeutics (BEAM) are experiencing notably high options trading volume today, with WVE's options activity representing 60.2% of its average daily stock volume and BEAM's at 55.8%. Specifically, the September 2025 $7.50 strike put for WVE and the September 2025 $20 strike call for BEAM are seeing particularly heavy trading, suggesting increased directional interest or hedging activity in these biotech names.

Analysis

Wave Life Sciences (WVE) and Beam Therapeutics (BEAM) are experiencing a significant surge in options market activity, indicating heightened investor interest and potential anticipation of future volatility. Today’s options volume for WVE, at 9,626 contracts, represents a substantial 60.2% of its average daily share volume. The activity is notably concentrated in the September 19, 2025, $7.50 strike put options, suggesting either significant hedging against a potential price decline below $7.50 or outright bearish speculation on a long-term basis. Similarly, BEAM's options volume of 13,366 contracts accounts for 55.8% of its average daily stock volume. For BEAM, the focus is on the bullish side, with heavy trading in the September 19, 2025, $20 strike call options. This points towards speculative bets on the stock's price appreciating beyond $20 over the next year. The concentration of volume in these specific long-dated strikes for both companies implies that market participants are establishing strategic positions ahead of expected, though unstated, long-term catalysts or valuation shifts.

Key Decisions for Investors

• Investors should investigate potential long-term catalysts for both WVE and BEAM, such as clinical trial data releases or regulatory milestones, that could be driving this specific, long-dated options activity.
• For those holding Wave Life Sciences (WVE), the high volume in far-dated puts at the $7.50 strike is a significant bearish signal that warrants a review of downside protection for existing long positions.
• The concentrated call buying in Beam Therapeutics (BEAM) at the $20 strike suggests bullish expectations, but investors should be prepared for heightened volatility as the market has now priced in a higher probability of significant price movement.
• Given the elevated options activity relative to stock volume, traders could consider using derivatives to define risk or express a view on the future direction of these two biotech stocks.